Evidence map›Paper›PMID 29328910›Full record

ArticleCell2018

Modulation of Myelopoiesis Progenitors Is an Integral Component of Trained Immunity.

Ioannis Mitroulis, Klara Ruppova, Baomei Wang, Lan-Sun Chen, Michal Grzybek, Tatyana Grinenko, Anne Eugster, Maria Troullinaki, Alessandra Palladini, Ioannis Kourtzelis and 18 more

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in Cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 671 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
671citing papers in PubMed, 1 pooled it
43.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04534803 phase3withdrawnnot on this mapstarted 2021, after this paper: background citation

Bacillus Calmette-Guerin Against Covid-19 for Prevention and Amelioration of Severity Trial

TypeinterventionalSponsorHarvard Medical School (HMS and HSDM)Ran2021 to 2022Enrolled0ConditionsCovid19ArmsBCG Vaccine, Placebo
NCT05677113 phase2active not recruitingnot on this mapstarted 2023, after this paper: background citation

A Phase II Study of Perioperative QBECO Site Specific Immunomodulator (Qu Biologics®) in Patients With Metastatic Colorectal Adenocarcinoma Within the Liver Undergoing Resection

TypeinterventionalSponsorSunnybrook Health Sciences CentreRan2023 to 2031Enrolled115ConditionsColorectal Cancer, Liver MetastasesArmsQBECO, Placebo
3 · Its place in the literature

Who cites it

671 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,026 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Trained Immunity in Childhood Vaccination.Acta paediatrica (Oslo, Norway : 1992) · 2026
    Review
  6. Monocytes in pneumonia: Functional plasticity and innate memory (Review).International journal of molecular medicine · 2026
    Review
  7. Review
  8. Myeloid cell reprogramming drives enhanced defense againstProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  9. Review
  10. Article
  11. Review
  12. Modeling the Exposome in Murine Cardiovascular Disease.JACC. Basic to translational science · 2026
    Review
  13. Review
  14. The theory of the inflammatory ecosystem.Science China. Life sciences · 2026
    Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. BCG HSP70 Reprograms Macrophages via Central Trained Immunity to Suppress Prostate Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article

611 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 12 institutions in 4 countries.

Ioannis MitroulisInstitute of Clinical Chemistry and Laboratory Medicine, Technische Universität Dresden, Dresden, Germany. Electronic address: ioannis.mitroulis@uniklinikum-dresden.de.
Klara RuppovaInstitute of Clinical Chemistry and Laboratory Medicine, Technische Universität Dresden, Dresden, Germany.
Baomei WangDepartment of Microbiology, University of Pennsylvania School of Dental Medicine, Philadelphia, PA, USA.
Lan-Sun ChenInstitute of Clinical Chemistry and Laboratory Medicine, Technische Universität Dresden, Dresden, Germany.
Michal GrzybekPaul Langerhans Institute Dresden, Helmholtz Zentrum München, University Hospital and Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany.
Tatyana GrinenkoInstitute of Clinical Chemistry and Laboratory Medicine, Technische Universität Dresden, Dresden, Germany.
Anne EugsterDFG-Center for Regenerative Therapies Dresden, Dresden, Germany.
Maria TroullinakiInstitute of Clinical Chemistry and Laboratory Medicine, Technische Universität Dresden, Dresden, Germany.
Alessandra PalladiniInstitute of Clinical Chemistry and Laboratory Medicine, Technische Universität Dresden, Dresden, Germany; Paul Langerhans Institute Dresden, Helmholtz Zentrum München, University Hospital and Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany.
Ioannis KourtzelisInstitute of Clinical Chemistry and Laboratory Medicine, Technische Universität Dresden, Dresden, Germany.
Antonios ChatzigeorgiouInstitute of Clinical Chemistry and Laboratory Medicine, Technische Universität Dresden, Dresden, Germany.
Andreas SchlitzerMyeloid Cell Biology, LIMES-Institute, University of Bonn, Bonn, Germany.
Marc BeyerDepartment of Genomics and Immunoregulation, Life and Medical Science Institute, University of Bonn, Bonn, Germany; Molecular Immunology in Neurodegeneration, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Leo A B JoostenDepartment of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, 6525 GA, Nijmegen, the Netherlands.
Berend IsermannInstitute of Clinical Chemistry and Pathobiochemistry, Otto von Guericke University, Magdeburg, Germany.
Mathias LescheDeep Sequencing Group, Biotechnology Center, Technische Universität Dresden, Dresden, Germany.
Andreas PetzoldDeep Sequencing Group, Biotechnology Center, Technische Universität Dresden, Dresden, Germany.
Kai SimonsMax Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany; Lipotype GmbH, Dresden, Germany.
Ian HenryMax Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany.
Andreas DahlDeep Sequencing Group, Biotechnology Center, Technische Universität Dresden, Dresden, Germany.
Joachim L SchultzeDepartment of Genomics and Immunoregulation, Life and Medical Science Institute, University of Bonn, Bonn, Germany; PRECISE - Platform for Single Cell Genomics and Epigenomics at the German Center for Neurodegenerative Diseases and the University of Bonn, Bonn, Germany.
Ben WielockxInstitute of Clinical Chemistry and Laboratory Medicine, Technische Universität Dresden, Dresden, Germany.
Nicola ZamboniInstitute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland.
Peter MirtschinkInstitute of Clinical Chemistry and Laboratory Medicine, Technische Universität Dresden, Dresden, Germany.
Ünal CoskunPaul Langerhans Institute Dresden, Helmholtz Zentrum München, University Hospital and Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany.
George HajishengallisDepartment of Microbiology, University of Pennsylvania School of Dental Medicine, Philadelphia, PA, USA.
Mihai G NeteaDepartment of Genomics and Immunoregulation, Life and Medical Science Institute, University of Bonn, Bonn, Germany; Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, 6525 GA, Nijmegen, the Netherlands.
Triantafyllos ChavakisInstitute of Clinical Chemistry and Laboratory Medicine, Technische Universität Dresden, Dresden, Germany. Electronic address: triantafyllos.chavakis@uniklinikum-dresden.de.
Technische Universität Dresden · DEDeutsches Diabetes-Zentrum e.V. · DEMax Planck Institute of Molecular Cell Biology and Genetics · DERadboud University Medical Center · NLUniversity of Pennsylvania · USBerlin-Brandenburger Centrum für Regenerative Therapien · DEEpigenomics (Germany) · DEETH Zurich · CHGerman Center for Neurodegenerative Diseases · DEOtto-von-Guericke University Magdeburg · DEPaul Langerhans Institute Dresden · DEUniversity of Bonn · DE

Funding

Local endogenous regulators of functional immune plasticity in the periodontiumR37DE026152 · NIDCR · UNIVERSITY OF PENNSYLVANIA · PI HAJISHENGALLIS, GEORGIOS · 2016 to 2025
$3.5M
Del-1: Molecular and Cellular Targets in PeriodontitisR01DE024716 · NIDCR · UNIVERSITY OF PENNSYLVANIA · PI HAJISHENGALLIS, GEORGIOS · 2015 to 2019
$2.0M
NIDCR NIH HHS R01 DE024716NIDCR NIH HHS R37 DE026152
6 · The paper itself

Abstract

Trained innate immunity fosters a sustained favorable response of myeloid cells to a secondary challenge, despite their short lifespan in circulation. We thus hypothesized that trained immunity acts via modulation of hematopoietic stem and progenitor cells (HSPCs). Administration of β-glucan (prototypical trained-immunity-inducing agonist) to mice induced expansion of progenitors of the myeloid lineage, which was associated with elevated signaling by innate immune mediators, such as IL-1β and granulocyte-macrophage colony-stimulating factor (GM-CSF), and with adaptations in glucose metabolism and cholesterol biosynthesis. The trained-immunity-related increase in myelopoiesis resulted in a beneficial response to secondary LPS challenge and protection from chemotherapy-induced myelosuppression in mice. Therefore, modulation of myeloid progenitors in the bone marrow is an integral component of trained immunity, which to date, was considered to involve functional changes of mature myeloid cells in the periphery.

Indexed as

Immunity, InnateImmunologic MemoryAnimalsbeta-GlucansCells, CulturedGranulocyte-Macrophage Colony-Stimulating FactorInterleukin-1betaMaleMiceMice, Inbred C57BLMyeloid Progenitor CellsMyelopoiesisbeta-GlucansGranulocyte-Macrophage Colony-Stimulating FactorInterleukin-1betacholesterol biosynthesisglycolysisGM-CSFinflammationinnate immune memoryinterleukin-1βmyelopoiesismyelosuppressiontrained innate immunityβ-glucan

Identifiers

PMID29328910
PMCPMC5766828
OpenAlexW2783037826

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.